Bell Global Equities Fund reported that DexCom's management presented robust growth targets through 2030 at its Investor Day, reassuring investors and driving a more than 25% share price increase between the event and month-end. The fund noted that despite consistently beating consensus expectations, DexCom's valuation had been subdued due to market skepticism about its long-term growth runway. The positive shift in sentiment made DexCom one of the portfolio's top monthly contributors. Bell Global Equities Fund retains its position, believing the valuation still underappreciates the penetration potential of the continuous glucose monitoring technology.
DexCom IncInvestor day presentation with robust growth targets through 2030, driving share price increase and positive sentiment shift.